Abiopharma

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

New Form 8-K - RECURSION PHARMACEUTICALS, INC. Filed: 2025-07-08 AccNo: 0001193125-25-156440 Size: 189 KB Item 3.02: Unregistered Sales of Equity Securities Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Brookdale Senior Living Inc. Filed: 2025-07-08 AccNo: 0001332349-25-000113 Size: 529 KB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 424B7 - RECURSION PHARMACEUTICALS, INC. Filed: 2025-07-08 AccNo: 0001193125-25-156439 Size: 530 KB

New Form 6-K - LakeShore Biopharma Co., Ltd. Filed: 2025-07-08 AccNo: 0001213900-25-061916 Size: 25 KB

New Form 8-K - Xtant Medical Holdings, Inc. Filed: 2025-07-08 AccNo: 0001641172-25-018092 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Progyny, Inc. Provides Business Update and Announces Details for Its Second Quarter 2025 Results Report

New Form 8-K - enGene Holdings Inc. Filed: 2025-07-08 AccNo: 0000929638-25-002520 Size: 240 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

New Form 8-K - Rallybio Corp Filed: 2025-07-08 AccNo: 0001739410-25-000100 Size: 173 KB Item 1.01: Entry into a Material Definitive Agreement Item 2.01: Completion of Acquisition or Disposition of Assets Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

enGene Announces Board and Leadership Appointments to Support Commercial Readiness

SeaStar Medical - SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)

Johnson & Johnson - Supplemental new drug application submitted to U.S. FDA for CAPLYTA® (lumateperone) with data demonstrating significant schizophrenia relapse prevention compared to placebo

Vaxart Announces Trading on OTCQX Best Market